title: Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.
abstract: We used a degenerate RT-PCR screen and subsequent real-time quantitative RT-PCR assays to examine the expression of HOX and TALE-family genes in 34 cases of chromosomally defined AML for which outcome data were available. AMLs with favorable cytogenetic features were associated with low overall HOX gene expression whereas poor prognostic cases had high levels. Characteristically, multiple HOXA family members including HOXA3-HOXA10 were jointly overexpressed in conjunction with HOXB3, HOXB6, MEIS1 and PBX3. Higher levels of expression were also observed in the FAB subtype, AML-M1. Spearmann correlation coefficients indicated that the expression levels for many of these genes were highly inter-related. While we did not detect any significant correlations between HOX expression and complete response rates or age in this limited set of patients, there was a significant correlation between event-free survival and HOXA7 with a trend toward significance for HoxA9, HoxA4 and HoxA5. While patients with elevated HOX expression did worse, there were notable exceptions. Thus, although HOX overexpression and clinical resistance to chemotherapy often coincide, they are not inextricably linked. Our results indicate that quantitative HOX analysis has the potential to add new information to the management of patients with AML, especially where characteristic chromosomal alterations are lacking.
authors.affiliation: Division of Medical Oncology, University of Colorado Health Sciences and Cancer Centers, Denver, CO 80262, USA.
authors.forename: H A
authors.initials: HA
authors.lastname: Drabkin
authors.forename: C
authors.initials: C
authors.lastname: Parsy
authors.forename: K
authors.initials: K
authors.lastname: Ferguson
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: L
authors.initials: L
authors.lastname: Lacotte
authors.forename: L
authors.initials: L
authors.lastname: Roy
authors.forename: C
authors.initials: C
authors.lastname: Zeng
authors.forename: A
authors.initials: A
authors.lastname: Baron
authors.forename: S P
authors.initials: SP
authors.lastname: Hunger
authors.forename: M
authors.initials: M
authors.lastname: Varella-Garcia
authors.forename: R
authors.initials: R
authors.lastname: Gemmill
authors.forename: F
authors.initials: F
authors.lastname: Brizard
authors.forename: A
authors.initials: A
authors.lastname: Brizard
authors.forename: J
authors.initials: J
authors.lastname: Roche
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics; D003199:Computer Systems; D017931:DNA Primers; D005260:Female; D005500:Follow-Up Studies; D005784:Gene Amplification; D020869:Gene Expression Profiling / Q000379:methods*; D015973:Gene Expression Regulation, Leukemic; D005801:Genes, Homeobox; D018398:Homeodomain Proteins / Q000096:biosynthesis; D006801:Humans; D007951:Leukemia, Myeloid / Q000145:classification / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D005810:Multigene Family; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017931:DNA Primers; D018398:Homeodomain Proteins; D009363:Neoplasm Proteins